

AltaMed COVID-19 Vaccine Update

3/16/2021

Prepared By: Sherrill Brown, MD, Medical Director of Infection Prevention



Overarching Goals & Guiding Principles

What are we trying to accomplish?


- Following local county prioritization tiers, vaccinate as many patients as possible while continuing to deliver primary medical care.

Approach

- Identify HUBS throughout LA County clinics and Pace Centers to distribute vaccines to our patients to maximize access and efficiency, but minimize a large volume of dedicated staffing.
- Partner with our Pharmacy team to manage inventory and administration.
- Focus on areas identified in key, targeted areas identified as priority focus areas.

Limitations/Constraints


- Identifying staff dedicated to vaccinations
- Weekly commitment to delivering vaccines that are distributed to us.
- During March, Blue Shield will be taking over distribution in California and we need to onboard to utilizing their system.




Vaccines To Date

>15,919 Vaccines Given


1,927 Employees Fully Vaccinated



Employee Vaccination Summary by Executive Leadership Team



Administered by County (running)



Patients with at least 1 dose (CA Index)

Very High (>.7500) 75th Percentile	53.54%	2,132
High (>.5000) 50th Percentile	32.40%	1,290
Medium (>.2500) 25th Percentile	10.42%	415
Low (<.2500)	3.64%	145
Grand Total		3,982

PERCENT OF POPULATION OF LA COUNTY RESIDENTS 65 AND OLDER WHO HAVE RECEIVED AT LEAST 1 DOSE OF VACCINE, BY RACE/ETHNICITY

(LOS ANGELES COUNTY RESIDENTS 16 AND OLDER WHO HAVE RECEIVED AT LEAST 1 DOSE OF VACCINE)
(AS OF 03/08/21)*

Race/Ethnicity	Number of People 65 and Older Who Have Received at Least 1 Dose of Vaccine	Population 65** and older	% of Population 65 and Older Who Have Received at Least 1 Dose of Vaccine
American Indian/Alaska Native***	1,804	3,759	48.0%
Asian	140,531	263,775	53.3%
Black/African American	49,041	126,732	38.7%
Latinx	176,862	406,155	43.5%
White	320,705	570,351	56.2%
Multi-Race†	10,776	--	--
Other†	91,645	--	--
Unknown	20,639	--	--
Total	815,271	1,373,617	59.3%

NOTE: Data for the Native Hawaiian/Pacific Islander group are not presented due to likely inaccurate estimates.

*People for whom both age and race/ethnicity data are available from California Immunization Registry (CAIR)/Prepmod data system/hospital line list

**Population of Los Angeles County residents (including Long Beach and Pasadena), who are 65 years and older, in each racial/ethnic group

***Number vaccinated may be overestimated due to inclusion of some Multi-race individuals. Population 65 and older is likely underestimated due to primarily consisting of those who identify as AIAN only. % of population vaccinated, therefore, may be an overestimate.

†Population estimates do not have "Multi-Race" or "Other" categories, therefore percents could not be calculated for these groups

Data source for population estimates: July 1, 2019 Population and Poverty Estimates, prepared by Hedderson Demographic Services for Los Angeles County Internal Services Department, released 05/26/2020

Eligibility Criteria: AltaMed Criteria

The COVID-19 Vaccine is free to all eligible persons.
Immigration status and insurance are not required.
Medical information is protected by law.

NOW VACCINATING

PHASE 1A

- Healthcare Workers
- Staff & Residents at Skilled Nursing Facilities
- Staff & Residents at Long-Term Care Facilities

PHASE 1B

Tier 1

- LA County Residents 65 and Older
- Education and Childcare - [More info](#)
- Emergency Services - [More info](#)
- Food and Agriculture - [More info](#)
- People with Serious Health Conditions/Disabilities
- People Who Live or Work in Congregate Living Spaces
- Janitorial, Custodial, and Maintenance Services
- Transportation and Logistics

Eligibility Criteria: Childcare

- License and license-exempt CHILDCARE service providers (Infants, Pre-Kindergarten, Transitional Kindergarten)
 - Center-based Early Care Education
 - Family Child Care Homes (FCC) – includes STAFF working at a family childcare
 - School district-based Early Care Education
 - Family, Friends & Neighbors (FFN) providing subsidized care
 - Family members residing in a home where a licensed family childcare is located
- Early care and education support staff from Resources and Referral agencies, Alternative Payment agencies, and California Community Care Licensing.
- Youth recreation staff who work directly with children: (Boys and Girls Clubs, YMCA, community-based organizations)
- Staff who work directly with children/youth as part of programming with the LA County Natural History Museum, and LA County and Cities Parks & Recreation, Public Library, and Beaches & Harbor departments
- Custodial staff and janitors

Exception: the following people are NOT eligible

- ✗ Private nannies and babysitters
- ✗ Homeschooling parents/guardians
- ✗ Parents/guardians assisting with cooperative early care education
- ✗ Private tutors
- ✗ Driver training instructors

Eligibility Criteria: Chronic Conditions

- **Cancer**, current with weakened immune system
- **Chronic kidney disease**, stage 4 or above
- **Chronic pulmonary disease**, oxygen dependent
- **Down syndrome**
- **Solid organ transplant**, leading to a weakened immune system
- **Pregnancy**
- **Sickle cell disease**
- **Heart conditions**, such as heart failure, coronary artery disease, or cardiomyopathies (but not hypertension)
- **Severe obesity** (Body Mass Index of 40 or greater, [CDC BMI Calculator](#))
- **Type 2 diabetes mellitus** with hemoglobin A1c level greater than 7.5%
- **People who, as a result of a developmental or other significant high-risk disability**, meet one or more of the following criteria:
 - A COVID-19 infection is likely to result in severe life-threatening illness or death; OR
 - Acquiring COVID-19 will limit the individual's ability to receive ongoing care or services vital to their well-being and survival; OR
 - Providing adequate and timely COVID care will be particularly challenging as a result of the individual's disability.

The three criteria above include people with a range of physical and behavioral disabilities including

- Individuals with severe behavioral health issues and substance use disorders
- Enrolled consumers of
 - Regional Centers
 - Independent Living Centers
 - In-Home Supportive Services
 - Community Based Adult Services
 - Medi-Cal HIV/AIDS Waiver
 - Medi-Cal Home and Community-Based Alternatives (HCBA) Waiver
 - Medi-Cal Assisted Living Waiver (ALW)
 - Program of All-Inclusive Care for the Elderly (PACE)
 - California Children's Services (CSS) Program (if the child is 16-21 years old)
 - California Genetically Handicapped Persons Program (GHPP)

Eligibility Criteria: Chronic Conditions

- Patients will attest that they meet eligibility criteria.
- Documentation will be encouraged but not required to receive the vaccine.

How to schedule an appointment?

1. Patients can be directed to call the vaccine hotline at: 888-909-5232.
 - a. Phone number is built into smartphrase for .COVIDVACCINECONSULT
2. You can instruct your support staff to schedule patient into vaccine schedule at the locations we are vaccinating.

- a. Nurse Schedule

- Anaheim Urgent Care Daily-COVID Dose 1 or 2
- Pico Passons Family Medicine Thursdays-COVID Dose 1 or 2
- Huntington Park Family Medicine Mondays-COVID Dose 1 or 2

- b. Pharmacy Schedule

Pico Passons

Huntington Park

Garden Grove

South Gate

West Covina (Saturday)

Commerce

Boyle Heights

Santa Ana Bristol

Goodrich (Saturday)

U.S. reports to VAERS after COVID-19 vaccination through February 16, 2021*

Vaccine	N	Non-serious AEs (%)	Serious AEs ^{†§} (%)
Moderna	56,567	54,708 (97)	1,859 (3)
Pfizer-BioNTech	48,196	43,974 (91)	4,222 (9)
Total	104,763	98,682 (94)	6,081 (6)

* Total pre-processed reports (reports received and classified as serious or non-serious)

† Based on the Code of Federal Regulations if one of the following is reported: death, life-threatening illness, hospitalization, prolongation of hospitalization, permanent disability, congenital anomaly or birth defect

§ Most commonly reported serious adverse events include death (456 reports of death following Moderna vaccine and 510 following Pfizer-BioNTech vaccine), dyspnea, pyrexia, SARS-CoV-2 test

Closed Caption is available

Most commonly reported adverse events to VAERS after COVID-19 vaccination through February 16, 2021*

Pfizer-BioNTech

Adverse event [†]	N (%)
Headache	2,322 (20.0)
Fatigue	1,801 (15.5)
Dizziness	1,659 (14.3)
Pyrexia	1,551 (13.4)
Chills	1,508 (13.0)
Nausea	1,482 (12.8)
Pain	1,464 (12.6)
SARS-CoV-2 Test Positive	1,002 (8.6)
Injection Site Pain	997 (8.6)
Pain in Extremity	923 (8.0)

Moderna

Adverse event [†]	N (%)
Headache	1,353 (23.4)
Pyrexia	1,093 (18.9)
Chills	1,056 (18.3)
Pain	945 (16.3)
Fatigue	888 (15.4)
Nausea	884 (15.3)
Dizziness	792 (13.7)
Injection Site Pain	671 (11.6)
Pain in Extremity	576 (10.0)
Dyspnoea	487 (8.4)

- No empirical Bayesian data mining alerts (EB05 ≥ 2) detected for any adverse event-COVID-19 vaccine pairs (most recent weekly results)

* For reports received and processed (coded, redacted, and quality assurance performed)

[†]Adverse events are not mutually exclusive



V-safe pregnancy registry enrollment as of February 19, 2021

Registry participants to date (N = 1,949)

Enrolled	1,815
Not eligible*	103
Refused/declined†	31

- In the enrolled population, there have been 275 completed pregnancies, including 232 live births
 - Other outcomes include miscarriage, stillbirth, ectopic/tubal, other

* Eligibility assessment determines whether vaccination was during pregnancy or within 30 days of last menstrual period

V-safe pregnancy registry outcomes of interest in COVID-19 vaccinated pregnant women as of February 18, 2021*

Outcomes	Background rates*	V-safe pregnancy registry overall
Pregnancy outcome		
Miscarriage (<20 weeks)	26%	15% [†]
Stillbirth (≥20 weeks)	0.6%	<1%
Pregnancy complications		
Gestational diabetes	7-14%	10%
Preeclampsia or gestational hypertension [§]	10-15%	15%
Eclampsia	0.27%	0%
Intrauterine growth restriction	3-7%	1%
Neonatal		
Preterm birth	10.1%	10%
Congenital anomalies [‡]	3%	4%
Small for gestational age [^]	3-7%	4%
Neonatal death	0.38%	0%

About the COVID-19 Vaccines

Millions of Americans have been vaccinated to protect themselves against the COVID-19 virus. If you're wondering which vaccine is best for you, the short answer is **whichever one is available to you upon eligibility**. All the FDA-approved vaccines are safe and effective.

WHAT'S THE DIFFERENCE BETWEEN THE VACCINES?

All available COVID-19 vaccines have been shown to be highly effective at preventing serious impacts of the virus including hospitalizations and deaths. Their differences are primarily the dosage schedule and how they can be transported and stored, as shown below.

	PFIZER-BIONTECH	MODERNA	JOHNSON & JOHNSON
TYPE	mRNA	mRNA	Viral vector
DOSES	2	2	1
PEAK EFFECTIVENESS*	7 days after the second dose*	14 days after the second dose*	28 days after the single dose*
STORAGE TEMPERATURE	Requires ultra-cold storage	Requires cold storage	Can be stored at temperature of regular refrigerator

*All three vaccines begin to protect you soon after being administered, including with the first dose.

WHY DOES STORAGE TEMPERATURE MATTER?

All vaccines require refrigeration, and some require cold or ultra-cold storage that many facilities don't have. Each vaccine's storage temperature only matters for storage and transportation—it does not have an impact on the vaccine's effectiveness. The Johnson & Johnson vaccine can be stored in a regular refrigerator, so a local pharmacy or a doctor's office could potentially be a vaccination site, which would increase vaccine access.

HOW EFFECTIVE IS EACH VACCINE?

All three vaccines are highly effective at preventing COVID related hospitalizations and deaths. The single-dose Johnson & Johnson vaccine has been shown to be 85% effective in preventing COVID-19 hospitalizations and deaths, and, in clinical trials in the U.S., 72% protective against moderate COVID-19 disease. The Pfizer-BioNTech vaccine showed efficacy of 95% at preventing symptomatic COVID-19 infection after two doses and the Moderna vaccine was 94.1% effective at preventing symptomatic COVID-19 infection after the second dose.

Janssen COVID-19 vaccine: Phase III results

- **When:** Interim results: outcomes observed from November 2020-January 2021
- **Who:** Persons aged ≥ 18 years
- **Where:** United States, South Africa, Brazil, Chile, Colombia, Peru, and Argentina

Outcome	Events/Vaccine ^a (n/N)	Events/Placebo ^a (n/N)	Vaccine efficacy (95% CI)
Symptomatic Lab-confirmed ^{b, c, d}	173/19,514	509/19,544	66% (60, 72)
Hospitalization ^d	2/19,514	29/19,544	93% (71, 98)
Death ^d	0/21,895	7/21,888	

^a21,895 and 21,888 persons were randomized to vaccine and placebo

^bCases diagnosed ≥ 14 days post vaccination among persons without evidence of prior SARS-CoV-2 infection

^cPrimary efficacy population (per protocol); includes a total of 3113 person-years of observation in vaccine group and 3089 person-years in placebo group

^dCOVID-19 associated

Closing thoughts on COVID-19 vaccine safety (Feb 2021)

- 75 million COVID-19 vaccine doses have been administered in the United States through February 28
- Reactogenicity profiles of mRNA vaccines in **v-safe** monitoring are consistent with what was observed in clinical trials, and systemic and local reactions are most commonly reported to VAERS
- Anaphylaxis following both vaccines has been reported to VAERS, though rarely
- No other safety signals for serious adverse events have been detected in VAERS
- No safety concerns have been identified among VSD Rapid Cycle Analysis prespecified outcomes as of February 13
- No unexpected pregnancy or infant outcomes have been observed related to COVID-19 vaccination during pregnancy
- Safety monitoring in pregnant women is ongoing and planned in **v-safe**, VAERS, VSD, and CISA

Prepare for COVID-19 vaccine conversations



Choose to get vaccinated



Start conversations early



Engage in effective conversations



Be prepared for questions



Key Messages

1. You can help **stop** the pandemic by getting a COVID-19 vaccine
2. Get the **information** you need to choose to get vaccinated when its available to you
3. COVID-19 vaccines are safe **and** effective
4. COVID-19 vaccine will be **free** for you
5. After COVID-19 vaccination, you **might** have some side effects. These are normal signs that your body is building protection
6. You will still need to wear a mask and socially distance after getting each shot of the vaccine **for now**.

